Peer-reviewed veterinary case report
Reproductive and developmental toxicology studies with gantenerumab in PS2APP transgenic mice.
- Journal:
- Reproductive toxicology (Elmsford, N.Y.)
- Year:
- 2017
- Authors:
- Barrow, Paul et al.
- Affiliation:
- Roche Pharmaceutical Research and Early Development
- Species:
- rodent
Abstract
Gantenerumab is intended for the treatment of Alzheimer's disease. It is a fully human recombinant monoclonal IgG1 which binds aggregated forms of amyloid beta such as Aβ oligomers, fibrils and neuritic amyloid plaques. A full package of developmental and reproductive toxicity (DART) studies was performed in the PS2APP double-transgenic mouse model of Alzheimer's disease. A combined fertility and embryo fetal development study and a pre-and post-natal development study were performed. The PS2APP mouse model allowed a more complete DART evaluation than would have been possible in conventional species or strains which do not express the target antigen of gantenerumab. No developmental or reproductive hazards were identified.
Find similar cases for your pet
PetCaseFinder finds other peer-reviewed reports of pets with the same symptoms, plus a plain-English summary of what was tried across them.
Search related cases →Original publication: https://pubmed.ncbi.nlm.nih.gov/28754630/